Recombinant DLL4 Protein, Human Others The human DLL4 (NP_061947.1) (Met1-Pro524) was expressed with five amino acids (DDDDK) at the C-terminus The recombinant human DLL4 consists of 504a.a and predicts a molecular weight of 55 kDa.
$ $99 In stock
Formulation: The recombinant human DLL4 consists of 504a.a and predicts a molecular weight of 55 kDa.
Source: HEK293 Cells
Usage: Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Recombinant DLL4 Protein, Human -

Recombinant DLL4 Protein, Human

The product is for non-human research only. Not for therapeutic or veterinary use.

Catalog Number: BT-203269

Molecular Weight: The recombinant human DLL4 consists of 504a.a and predicts a molecular weight of 55 kDa.

Formulation: Recombinant DLL4 Protein was lyophilized from sterile PBS, pH 7.4.1

Source: HEK293 Cells

Product Name Recombinant DLL4 Protein, Human
Molecular Weight The recombinant human DLL4 consists of 504a.a and predicts a molecular weight of 55 kDa.
AA Sequence Met1-Pro524
Bioactivity Measured by the ability of the immobilized protein to enhance BMP2-induced alkaline phosphatase activity in C3H10T1/2 mouse embryonic fibroblast cells. The ED50 for this effect is typically 4-20 µg/mL in the presence of 500 ng/mL recombinant human BMP2.
Endotoxin < 1.0 EU per μg protein as determined by the LAL method
Formulation Recombinant DLL4 Protein was lyophilized from sterile PBS, pH 7.4.1
Host Species Homo sapiens (Human)
Description The human DLL4 (NP_061947.1) (Met1-Pro524) was expressed with five amino acids (DDDDK) at the C-terminus
Product Background Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.
Product Memo Delta-like 4 Protein, Human;hdelta2 Protein, Human
Product Type Recombinant Protein
Source HEK293 Cells
Storage Store recombinant protein under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Terminal Ser 27
Usage Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Last Modified Jul 26 2021